Neurocrine Biosciences, Inc. splits its revenue into 3 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Product at $2.8 billion, 99% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3,702
|
2,860
|
2,355
|
1,887
|
1,489
|
1,134
|
1,046
|
788
|
451
|
162
|
15
|
| Product |
3,683
+38.6%
share 99.5%
|
2,834
+21.6%
share 99.1%
|
2,331
+25.3%
share 99.0%
|
1,861
+29.1%
share 98.6%
|
1,441
+32.2%
share 96.8%
|
1,090
+9.7%
share 96.2%
|
994
+32.0%
share 95.0%
|
753
+83.8%
share 95.5%
|
410
+251.2%
share 90.8%
|
117
share 72.2%
|
—
|
| INGREZZA |
—
|
—
|
2,300
+27.8%
share 97.7%
|
1,800
+28.6%
share 95.4%
|
1,400
share 94.0%
|
—
|
—
|
—
|
—
|
—
|
—
|
| Collaboration Revenue |
19
-26.3%
share 0.5%
|
27
+7.7%
share 0.9%
|
25
-6.8%
share 1.0%
|
26
-44.6%
share 1.4%
|
48
+10.1%
share 3.2%
|
43
-16.2%
share 3.8%
|
52
+47.2%
share 5.0%
|
35
-15.4%
share 4.5%
|
42
-7.5%
share 9.2%
|
45
share 27.8%
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- NBIX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 914475
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.